Esperion (ESPR) released a press release today stating that their phase 3 CLEAR study met its primary endpoint (mortality benefit of at least 15%) yet the stock was down 15%. I don't get why. And before anyone says that a positive trial outcome was already “baked” in to the stock price, that clearly wasn't the case here. The drug and company have struggled since initial FDA approval in 2020.
Leave a Reply